Every Form 4 that Bicara Therapeutics Inc. (BCAX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BCAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAX filings page.
Bicara Therapeutics Inc. (BCAX) officer Ryan Cohlhepp, President, COO and Interim CEO, exercised options to acquire 17,500 shares of common stock on September 8, 2026 at an exercise price of $3.7898 per share, leaving 34,252 options outstanding under that grant. On the same date he sold 14,058 shares at a weighted average price of $22.7666 per share and 3,442 shares at a weighted average price of $23.4349 per share in multiple transactions. These trades were made pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026, and the option underlying the exercise vests in sixteen equal quarterly installments following April 5, 2023, subject to continued service.
Bicara Therapeutics Inc. reported that its Chief Financial Officer, Jennifer Larson, received a grant of 285,000 stock options on August 12, 2026. The options have an exercise price of $24.63 per share and are exercisable for an equal number of shares of common stock until August 12, 2036. According to the vesting terms, 25% of the options vest and become exercisable on August 12, 2027, with the remaining 75% vesting in twelve equal quarterly installments thereafter, subject to her continued service. Following this award, she holds 285,000 derivative securities of this type directly.
Bicara Therapeutics Inc. Chief Financial Officer Hyep Ivan exercised stock options for 12,500 shares of common stock at an exercise price of $3.7898 per share and on the same day sold 12,500 shares at a weighted average price of $27.9673 per share. The option exercise reduced the reported option position to 26,336 stock options following the transaction, with the options expiring on April 5, 2033 and vesting in sixteen equal quarterly installments following April 5, 2023. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
Bicara Therapeutics Inc. director and Chief Executive Officer Claire Mazumdar reported option exercises and stock sales dated August 10, 2026. She exercised 10,000 stock options at an exercise price of $3.7898 per share, acquiring 10,000 shares of common stock, and then sold 10,000 common shares at a weighted average price of $27.975 per share in multiple transactions. After the exercise, she directly held 110,546 stock options linked to this grant, which expires on April 5, 2033. These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
Bicara Therapeutics Inc. President and COO Ryan Cohlhepp reported an option exercise and same‑day share sale in Bicara Therapeutics Inc. On 2026-08-10 he exercised 18,750 stock options at an exercise price of $3.7898 per share, receiving 18,750 shares of common stock. The same day, he sold 18,750 common shares at a weighted average price of $27.9751 per share, with individual sale prices ranging from $27.56 to $28.41, pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. Following the derivative transaction, 51,752 stock options remained reported outstanding, expiring on 2033-04-05, from a grant that vests in sixteen equal quarterly installments after April 5, 2023, subject to continued service.
Bicara Therapeutics director Jeremy Bender reported an equity compensation award in the form of a Stock Option (Right to Buy) covering 38,950 shares of common stock. The option has an exercise price of $26.88 per share and expires on July 28, 2036. One-third of the shares underlying the option vest and become exercisable on July 28, 2027, with the remaining shares vesting in 24 equal monthly installments thereafter, subject to his continued service on each vesting date.
Bicara Therapeutics Inc. director Christy J. Oliger received a grant of stock options for 38,950 shares of common stock on July 28, 2026. The options have an exercise price of $26.88 per share, expire on July 28, 2036, and vest one-third on July 28, 2027, with the remaining two-thirds vesting in 24 equal monthly installments, subject to her continued service.
Bicara Therapeutics Inc. director and Chief Executive Officer Claire Mazumdar exercised options to acquire 10,000 shares of common stock at $3.7898 per share, then sold 10,000 shares in open-market transactions on July 10, 2026, pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026, and continues to hold shares directly.
Bicara Therapeutics Inc. director and President & COO Ryan Cohlhepp reported an exercise-and-sell transaction in company common stock. On July 8, 2026, he exercised stock options covering 18,750 shares of common stock at an exercise price of $3.7898 per share and received the underlying shares. On July 8–9, 2026, he executed open‑market sales totaling 28,750 shares at weighted average prices including $28.7589, $29.7961, $30.3549, and $29.00 per share. Following these transactions, he held 181,641 shares of common stock directly and 70,502 stock options directly. The sales were carried out under a pre‑arranged Rule 10b5-1 trading plan adopted on March 31, 2026.
Bicara Therapeutics Inc.'s Chief Financial Officer Ivan Hyep reported a set of July 8, 2026 equity transactions. He exercised stock options for 12,500 shares of common stock at an exercise price of $3.7898 per share and sold 28,000 common shares in open-market trades at weighted average prices between about $28.60 and $30.31. The sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2026.
Bicara Therapeutics Inc. reported a Form 4 showing a compensation-related stock option grant tied to entities associated with RA Capital. A stock option for 19,475 shares of Common Stock was granted to director Jake Simson at an exercise price of $20.56 per share, expiring on June 9, 2036. The option vests upon the earlier of June 9, 2027 or the next annual stockholders’ meeting, subject to his continued service. Under Dr. Simson’s arrangement, any net cash or stock from exercising the option is turned over to RA Capital Healthcare Fund LP and RA Capital Nexus Fund III LP to offset advisory fees. The reporting persons, including RA Capital Management, L.P. and its principals, disclaim beneficial ownership except for any pecuniary interest.
Bicara Therapeutics Inc. director Christopher Bowden reported a new stock option grant. He received options to buy 19,475 shares of common stock at an exercise price of $20.56 per share, expiring on June 9, 2036.
The options vest on the earlier of June 9, 2027 or the date of Bicara’s next Annual Meeting of Stockholders, if he continues serving through that date. Following this grant, Bowden holds stock options covering 19,475 shares directly.
Bicara Therapeutics Inc. director Kate Haviland received a stock option grant giving her the right to buy 19,475 shares of common stock at an exercise price of $20.56 per share. These options were granted at no cost and represent a compensation award rather than an open-market purchase.
The 19,475 underlying shares vest on the earlier of June 9, 2027 or the date of the company’s next Annual Meeting of Stockholders, provided she continues serving as a director through that vesting date. Following this grant, her reported option holdings from this award total 19,475 shares.
Bicara Therapeutics Inc. director Kiran Mazumdar-Shaw received a stock option grant covering 19,475 shares of common stock. The option has an exercise price of $20.56 per share and expires on June 9, 2036.
The shares underlying this option vest on the earlier of June 9, 2027 or the date of the next Annual Meeting of Stockholders, subject to her continued service on that vesting date. Following this grant, she holds 19,475 derivative securities directly.
Bicara Therapeutics Inc. director Robertson Scott M. received a grant of stock options on Common Stock. The award covers 19,475 stock options with an exercise price of $20.56 per share, expiring on June 9, 2036.
The options vest upon the earlier of June 9, 2027 or the date of the next Annual Meeting of Stockholders, subject to his continued service on that vesting date. Following this grant, he holds 19,475 stock options directly.
Bicara Therapeutics Inc. director Michael Powell received a grant of stock options as part of his compensation. The award covers 19,475 options to buy common stock at an exercise price of $20.56 per share, expiring on June 9, 2036.
The options vest upon the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, conditional on his continued service. After this grant, Powell holds 19,475 derivative securities directly, reflecting a routine equity incentive rather than an open-market purchase or sale.
Bicara Therapeutics Inc. reported that director Jake Simson was granted a stock option for 19,475 shares of common stock at an exercise price of $20.56 per share. The option vests on the earlier of June 9, 2027 or the next Annual Meeting of Stockholders, subject to his continued service.
According to the disclosed arrangement, Simson holds this option for the benefit of R.A. Capital Healthcare Fund, L.P. and R.A. Capital Nexus Fund III, L.P. and must turn over any net cash or stock received upon exercise to RA Capital Management, L.P., and therefore disclaims beneficial ownership of the option and underlying shares.
Bicara Therapeutics Inc.’s Chief Financial Officer Hyep Ivan reported a combination of option exercise and share sale. Ivan exercised stock options for 9,200 shares of common stock at an exercise price of $3.7898 per share, then sold 9,200 shares in an open-market transaction at a weighted average price of $20.4221 per share.
The sale was executed on May 21, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2025. Following these transactions, Ivan directly holds 145,355 shares of common stock and retains stock options covering 70,584 shares expiring on August 8, 2033, which vest in sixteen equal quarterly installments following August 8, 2023, subject to continued service.
Bicara Therapeutics Inc. Chief Executive Officer Claire Mazumdar reported a mix of stock sales and option exercises in common stock. She sold a total of 15,000 shares in open-market transactions at weighted average prices of $20.3481 and $19.9619 per share under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. She also exercised stock options to acquire 15,000 shares of common stock at an exercise price of $3.7898 per share. Following these transactions, she directly holds 362,152 shares of common stock and retains stock options covering 146,107 shares.
Bicara Therapeutics President and COO Ryan Cohlhepp reported routine transactions in company stock. On May 15, 2026, he sold a total of 12,500 shares of common stock in open-market trades at a weighted average price of $20.2919 per share under a pre-arranged Rule 10b5-1 trading plan. On the same date, he exercised stock options to acquire 8,000 shares of common stock at an exercise price of $3.7898 per share. Following these transactions, he held 191,641 shares of common stock directly and 101,334 stock options for additional shares.
Bicara Therapeutics Inc. reported that Chief Medical Officer William Schelman received a grant of stock options covering 85,000 shares of common stock. The options have an exercise price of $22.58 per share and expire on May 8, 2036.
According to the terms, the shares underlying this option vest in sixteen equal quarterly installments following May 8, 2026, contingent on his continued service. After this grant, Schelman holds options for 85,000 shares directly, reflecting a routine compensation-related award rather than an open-market trade.
Bicara Therapeutics Chief Medical Officer David Raben reported an option exercise and related share sale. He exercised stock options for 5,500 shares of common stock at an exercise price of $3.7898 per share, then sold 5,500 shares in an open-market transaction at a weighted average price of $22.8782 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025, and occurred through multiple trades between $22.51 and $23.07 per share. Following these transactions, Raben directly holds 55,286 shares of common stock and 41,913 stock options.
Bicara Therapeutics Chief Financial Officer Hyep Ivan exercised stock options and sold the resulting shares in a coordinated transaction. On April 21, 2026, he exercised options to acquire 9,200 shares of common stock at $3.7898 per share, then sold 9,200 shares in open-market trades at a weighted-average price of $23.0015 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2025. After the transactions, he directly owned 145,355 common shares and had 39,744 stock options remaining, with the option award scheduled to vest in sixteen equal quarterly installments following April 5, 2023 and expiring on April 5, 2033.
Bicara Therapeutics Inc. Chief Executive Officer Claire Mazumdar reported option exercises and a modest share sale. She exercised options to acquire a total of 37,760 shares of common stock at exercise prices of $3.7898, $4.4369, and $5.4537 per share, converting derivative awards into stock.
On the same date, she sold 15,000 shares of common stock in an open-market transaction at a weighted average price of $23.6097 per share, executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. After these transactions, she directly owns 362,152 shares of Bicara common stock.
Bicara Therapeutics President and COO Ryan Cohlhepp reported an option exercise and related stock sales in Bicara Therapeutics Inc. common stock. He exercised stock options for 8,000 shares at an exercise price of $3.7898 per share, acquiring the same number of common shares.
On the same date, he sold a total of 12,500 common shares at a weighted average price of $23.0073 per share, executed in multiple transactions under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly owns 196,141 common shares of Bicara Therapeutics Inc.
Bicara Therapeutics Chief Medical Officer David Raben reported an option exercise and related share sale. He exercised stock options to acquire 5,500 shares of common stock at an exercise price of $3.7898 per share, then sold 5,500 shares at a weighted average price of $18.9508 per share.
The filing states that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. Following these transactions, Raben directly holds 55,286 shares of Bicara Therapeutics common stock.
Bicara Therapeutics Inc. Chief Financial Officer Hyep Ivan exercised stock options and sold shares in a pre-planned transaction. On March 23, 2026, he exercised options for 9,200 shares of common stock at an exercise price of $3.7898 per share, then sold the same 9,200 shares at a weighted average price of $18.5161 per share in multiple trades between $18.15 and $18.84. The sale was carried out under a Rule 10b5-1 trading plan adopted on February 13, 2025, indicating the trades were pre-scheduled rather than opportunistic. Following these transactions, Ivan directly owned 145,355 shares of Bicara Therapeutics common stock. The exercised options were part of a grant vesting in sixteen equal quarterly installments after April 5, 2023 and are scheduled to expire on April 5, 2033.
Bicara Therapeutics Inc. director and Chief Executive Officer Claire Mazumdar exercised stock options and sold the related shares over three days. She exercised options for a total of 15,000 shares of Common Stock at an exercise price of $3.7898 per share, then sold 15,000 shares in open-market transactions at weighted-average prices between $18.73 and $19.26, as disclosed in the price ranges. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. Following the transactions, she holds 339,392 shares of Common Stock directly.
Bicara Therapeutics Inc.'s President and COO, Ryan Cohlhepp, exercised stock options for 8,000 shares of common stock at an exercise price of $3.7898 per share and then sold 12,500 shares of common stock at a weighted average price of $19.6571 per share. The sales were executed on March 16, 2026 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. Following these transactions, he directly holds 200,641 shares of Bicara common stock.
Bicara Therapeutics Inc. Chief Executive Officer Claire Mazumdar exercised options to acquire 36,766 shares of common stock at an exercise price of $3.7898 per share on March 9, 2026. She then sold 36,766 shares of common stock at a weighted average price of $19.1660 per share in open-market transactions executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. Following these transactions, she directly holds 339,392 shares of Bicara Therapeutics common stock.
Bicara Therapeutics director and Chief Executive Officer Claire Mazumdar reported a series of option exercises and related share sales. Over March 4–6, 2026, she exercised stock options to acquire a total of 8,234 shares of common stock at an exercise price of $3.7898 per share.
On each day, the same number of shares was sold in open‑market transactions, totaling 8,234 shares sold at weighted average prices around $18.73–$18.92. These transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on February 12, 2025. Following these trades, Mazumdar directly owned 339,392 shares of common stock and held 233,476 stock options.
Bicara Therapeutics director and President/COO Ryan Cohlhepp exercised stock options and sold shares of the company on March 3, 2026. He exercised options for 12,892 shares of common stock and then sold a total of 17,392 shares in open-market transactions.
The sales, executed under a Rule 10b5-1 trading plan adopted on February 12, 2025, occurred at a weighted average price of $18.1631 per share, with individual trades ranging from $18.00 to $18.32. After these transactions, he directly held 205,141 shares of Bicara common stock.
Bicara Therapeutics Chief Financial Officer Hyep Ivan reported option exercises and share sales in early March 2026. On March 3–4, he exercised stock options to acquire a total of 16,518 shares of common stock at a reported exercise price of $3.7898 per share. He then sold 16,518 common shares in two open-market transactions at weighted-average prices of $18.2154 and $18.2456 per share, under a Rule 10b5-1 trading plan adopted on February 13, 2025.
After these transactions, he directly owned 145,355 shares of Bicara common stock and held stock options covering 79,784 shares, subject to vesting in equal quarterly installments following April 5, 2023 and August 8, 2023, contingent on his continued service.
Bicara Therapeutics Chief Medical Officer David Raben reported a series of option exercises and related stock sales in early March 2026. He exercised stock options for a total of 16,500 shares of common stock at an exercise price of $3.7898 per share, converting derivative awards into common shares.
On the same dates, he sold 16,500 shares of Bicara Therapeutics Inc. common stock in open-market transactions at prices including $18.4500 and a weighted average of $18.5227 per share, with sale prices ranging from $18.45 to $18.72, pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. After these transactions, he directly owned 55,286 shares of common stock.
Bicara Therapeutics Inc. reported insider purchases by RA Capital–affiliated funds. On February 26, 2026, entities managed by RA Capital Management, L.P. bought 2,200,000 Pre-Funded Warrants at $15.9999 per right and 300,000 shares of common stock at $16.00 per share in open-market or private transactions.
The Pre-Funded Warrants have no expiration date and are exercisable at any time after issuance, but cannot be exercised if the holder and its affiliates would own more than 9.99% of outstanding common stock after exercise. The RA Capital adviser, its general partner, the funds, and principals Dr. Peter Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership except to the extent of their pecuniary interests.
Bicara Therapeutics Inc. director and President/COO Ryan Cohlhepp reported a set of transactions on common stock tied to stock options. He exercised stock options for 3,108 shares of common stock at an exercise price of $3.7898 per share. On the same date, he sold a total of 3,631 common shares in open-market transactions at a weighted average price of $18.0395 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. After these trades, he directly owned 209,641 shares of Bicara Therapeutics common stock.
Bicara Therapeutics Inc. reported that President and COO, and director, Ryan Cohlhepp received a stock option award. The option gives him the right to buy 300,000 shares of common stock at an exercise price of $16.76 per share, granted on February 2, 2026.
The option expires on February 2, 2036 and vests in sixteen equal quarterly installments after February 2, 2026, as long as he continues serving the company on each vesting date. Following this grant, he beneficially owns 300,000 derivative securities directly.
Bicara Therapeutics Inc. reported that Chief Executive Officer and director Claire Mazumdar received a grant of stock options. On February 2, 2026, she was awarded options to purchase 450,000 shares of Bicara common stock at an exercise price of $16.76 per share.
The options vest in sixteen equal quarterly installments after February 2, 2026, and each vesting date requires her continued service with the company. Following this grant, she holds 450,000 stock options directly.
Bicara Therapeutics Inc. reported a new stock option grant to its Chief Medical Officer, David Raben. On February 2, 2026, he received a stock option covering 100,000 shares of common stock at an exercise price of $16.76 per share, expiring on February 2, 2036.
The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, and each installment requires his continued service on the vesting date. Following this grant, he beneficially owns 100,000 derivative securities directly.
Bicara Therapeutics reported that its Chief Financial Officer, Hyep Ivan, received a grant of stock options on February 2, 2026. The award covers 125,000 stock options, each allowing the purchase of one share of common stock at an exercise price of $16.76 per share.
The options vest in sixteen equal quarterly installments after February 2, 2026, and require the CFO’s continued service on each vesting date. Following this grant, the reporting person beneficially owns 125,000 derivative securities directly.
Bicara Therapeutics Inc. reported that its Chief Legal Officer, Lara Meisner, received a grant of stock options on February 2, 2026. The award covers 90,000 options to buy common stock at an exercise price of $16.76 per share.
The options vest in sixteen equal quarterly installments following February 2, 2026, and each vesting event requires Meisner’s continued service with the company. After this grant, she directly holds 90,000 derivative securities in the form of stock options.
Bicara Therapeutics Inc. President and COO Ryan Cohlhepp, who is also a director, reported selling 3,828 shares of common stock on January 22, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025, which is designed to allow insiders to trade on a scheduled basis. The shares were sold at a weighted average price of $18.1024, with individual trade prices ranging from $18.00 to $18.19. Following this transaction, Cohlhepp directly beneficially owns 210,164 shares of Bicara common stock.
Bicara Therapeutics Inc. Chief Financial Officer Hyep Ivan reported an option exercise and matching share sale on January 22, 2026. Ivan exercised a stock option for 1,882 shares of common stock at $3.7898 per share, then sold 1,882 common shares at a weighted average price of $18.1522 under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2025. Following these transactions, Ivan directly holds 145,355 shares of common stock and 65,462 stock options. The option underlying the exercised shares vests in sixteen equal quarterly installments following April 5, 2023, subject to continued service.
Bicara Therapeutics Inc. President and COO Ryan Cohlhepp, who also serves as a director, reported a small open-market sale of company stock. On January 15, 2026, he sold 149 shares of Common Stock at a price of $18.02 per share, coded as a sale transaction. After this trade, he beneficially owned 213,992 shares of Bicara Therapeutics Common Stock in direct ownership form. The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan that was adopted on February 12, 2025, indicating it was pre-arranged under SEC rules.
Bicara Therapeutics Inc. disclosed that its Chief Executive Officer and director exercised stock options and acquired common shares. On 12/16/2025, the reporting person exercised a stock option and acquired 29,500 shares of common stock at an exercise price of $5.4537 per share. After this transaction, the reporting person beneficially owned 339,392 shares of common stock directly.
The exercised option was part of a larger grant of stock options with an exercise price of $5.4537, originally covering shares of common stock and expiring on 12/14/2033. Following the reported transaction, the reporting person held 565,512 stock options directly. The option grant vests in sixteen equal quarterly installments following December 14, 2023, subject to the reporting person’s continued service.
Bicara Therapeutics reported insider transactions by its President and COO, who is also a director. On December 15, 2025, the insider exercised stock options for 8,000 shares of common stock at an exercise price of $3.7898 per share and, in separate trades, sold 8,000 and 4,500 shares of common stock at a weighted average price of $18.6838 per share under a Rule 10b5-1 trading plan adopted on February 12, 2025.
After these transactions, the insider directly owned 189,141 shares of Bicara common stock and held 141,334 stock options. The option covers 8,000 underlying shares in this transaction, carries a $3.7898 exercise price, expires on August 8, 2033, and vests in sixteen equal quarterly installments following August 8, 2023, subject to continued service.
Bicara Therapeutics Inc. (BCAX) reported insider transactions by its Chief Financial Officer on Form 4. On November 21, 2025, the CFO exercised 605 stock options at $3.7898 per share and sold 605 shares of common stock at a price of $18.15 per share. On November 24, 2025, the CFO exercised an additional 17,795 options at $3.7898 and sold 17,795 shares at a weighted average price of $18.5498, with sales occurring between $18.15 and $18.84. After these trades, the CFO beneficially owned 145,355 shares of common stock directly and held 98,184 stock options. The transactions were carried out under a Rule 10b5-1 trading plan adopted on February 13, 2025.
Bicara Therapeutics Inc. insider transaction: On 11/21/2025, a reporting person who is both a director and the President and COO of Bicara Therapeutics Inc. (BCAX) exercised a stock option for 8,000 shares of common stock at an exercise price of $3.7898 per share and then sold shares of common stock on the same day.
The insider reported selling 8,000 shares of common stock at a weighted average price of $18.047 per share and an additional 4,500 shares at the same weighted average price, executed in multiple trades between $18.00 and $18.14. After these transactions, the insider beneficially owned 193,641 shares of common stock directly and 149,334 stock options. The option for 8,000 shares was granted on August 8, 2023 and vests in sixteen equal quarterly installments, contingent on continued service, and was exercised under a Rule 10b5-1 trading plan adopted on February 12, 2025.
Bicara Therapeutics Inc. (BCAX) reported an insider transaction by its Chief Executive Officer, who is also a director. On 11/24/2025, the reporting person exercised stock options for 41,163 shares of common stock at an exercise price of $3.7898 per share and then sold 41,163 shares of common stock at a weighted average price of $18.8623 per share under transaction code "S".
The option exercised is a stock option (right to buy) covering 41,163 shares of common stock, with an exercise price of $3.7898, expiring on 08/08/2033. The filing states that these option shares vest in sixteen equal quarterly installments following August 8, 2023, subject to continued service. After the reported transactions, the reporting person beneficially owns 309,892 shares of common stock and 236,107 stock options, all held directly. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
Bicara Therapeutics Inc. (BCAX) reported insider transactions by its Chief Medical Officer, who filed a Form 4 as a single reporting person. On 11/24/2025 and 11/25/2025, the officer exercised stock options to acquire common shares at an exercise price of $3.7898 per share and sold the same number of shares on each corresponding date.
On 11/24/2025, 5,500 shares of common stock were acquired through an option exercise and 5,500 shares were sold at $18.45 per share, leaving 35,497 shares owned directly. On 11/25/2025, additional option exercises and sales covered 4,594 and 906 shares, with sales at a weighted average price of $18.8424. After these transactions, the officer directly owned 35,497 common shares and held stock options covering 69,413 shares, subject to the vesting schedules described.
The filing notes that these trades were made under a Rule 10b5-1 trading plan adopted on February 12, 2025, with certain sale prices reported as weighted averages across multiple individual transactions.